Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  anti-thymocyte globulin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 131 for your search:
Start Over
Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: SMD/ATG-CSA/2002, NCT00488436
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 50 and under
Sponsor: Other
Protocol IDs: CDR0000066400, MSGCC-9739, NCI-V98-1433, NCT00003398
Phase II/III Randomized Study of Transplantation With Unmodified Versus T-Cell-Depleted, Unrelated Allogeneic Bone Marrow in Patients With Leukemia (Summary Last Modified 12/2000)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: Under 46
Sponsor: Other
Protocol IDs: UMN-MT-1995-06, UMN-9224, UMN-MT-9506, NCI-V00-1605, NCT00006451
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 4 to 70
Sponsor: Other
Protocol IDs: CDR0000066968, RP 98-15, RPCI-RP-9815, NCI-V99-1527, NCT00003816
Stem Cell Transplant for Bone Marrow Failure Syndromes
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 35 and under
Sponsor: Other
Protocol IDs: MT2000-18, 9504M09637, NCT00176878
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: EudraCT:2005-000805-68, NCT00354120
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 1 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABX-CB-9906, UCLA-9911052, NCI-G01-1916, NCT00012077, NCT00035880
Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: SAKK 33/99, SWS-SAKK-33/99, NCT00004208
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 30
Sponsor: NCI, Other
Protocol IDs: AAML0531, COG-AAML0531, CDR0000487497, NCT00372593
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 12 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: PROGAST, NCT00180089
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 2005-0366, NCI-2012-01475, CA55164, NCT00469144
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: ATGFamilyStudy, NCT00678275
ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
Phase: Phase III
Type: Treatment
Status: Closed
Age: 3 months to 18 years
Sponsor: Other
Protocol IDs: EudraCT 2005-005106-23, NCT01423500
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 3 months to 18 years
Sponsor: Other
Protocol IDs: ALL-SZT- BFM 2003, NCT01423747
Phase I/II Study of HLA Matched, Related Donor Umbilical Cord and Placental Blood in Patients With Hematologic Malignancies and Disorders
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 55 and below
Sponsor: NCI
Protocol IDs: FHCRC-1126.00, NCI-V97-1211
Phase I/II Study of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Relatives for Children with Hematologic Malignancy (Summary Last Modified 12/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 17 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP-0134-004, NCI-V97-1219
Phase I/II Study of Patients With Hematologic Malignancies and Disorders Transplanted With HLA Haploidentical Related Donor Umbilical Cord and Placenta Blood
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 55 and under
Sponsor: NCI
Protocol IDs: FHCRC-1127.00, NCI-G97-1230
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 17 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000462443, UCSF-01152, UCSF-H411-17802-06, NCT00305708
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: BMTCTN0301, U01HL069294, 5U01HL069294-05, FHCRC-2051.00, NCT00326417
Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: EK126092000, NCT00460629
Start Over